Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -20059.90% is 128% below its 5-year average of -8807.76%, around the middle of its 5-year range (-58513.33%–26312.73%).
39.88% above its 12-month average of -33365.70%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -14915.56%.
NET PROFIT MARGIN
-20059.90%
NET PROFIT MARGIN AVG TTM
-33365.70%
NET PROFIT MARGIN AVG 3Y
-9209.68%
NET PROFIT MARGIN AVG 5Y
-8807.76%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+39.88%
CURRENT VS 3Y AVG
-117.81%
CURRENT VS 5Y AVG
-127.75%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 509 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Clene Inc.
Market Cap
$49.84M
Net Profit Margin
-20059.90%
TTM Avg
-33365.70%
3Y Avg
-9209.68%
5Y Avg
-8807.76%
Market Cap
$48.63M
Net Profit Margin
-375.77%
TTM Avg
-226.26%
3Y Avg
-308.90%
5Y Avg
-527.22%
Market Cap
$51.17M
Net Profit Margin
-128.69%
TTM Avg
-13664.85%
3Y Avg
-30726.86%
5Y Avg
-811138.03%
Market Cap
$51.78M
Net Profit Margin
-11304.83%
TTM Avg
-9549.74%
3Y Avg
-8821.76%
5Y Avg
-6347.57%
Market Cap
$51.84M
Net Profit Margin
-91866.00%
TTM Avg
-196225.86%
3Y Avg
-104777.73%
5Y Avg
-90977.38%
Market Cap
$47.64M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
-9.50%
5Y Avg
-48.42%
Market Cap
$53.11M
Net Profit Margin
N/A
TTM Avg
-24.71%
3Y Avg
-12.36%
5Y Avg
-8.24%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Clene Inc. (CLNN) | $49.84M | -20059.90% | -33365.70% | -9209.68% | -8807.76% |
| biote Corp. (BTMD)vs › | $50.25M | 3.19% | 7.83% | 4.22% | 10.88% |
| Celularity Inc. (CELU)vs › | $48.63M | -375.77% | -226.26% | -308.90% | -527.22% |
| Apollomics, Inc. (APLM)vs › | $51.17M | -128.69% | -13664.85% | -30726.86% | -811138.03% |
| eXoZymes, Inc. (EXOZ)vs › | $51.23M | 0.00% | 0.00% | 0.00% | 0.00% |
| Envoy Medical, Inc. (COCH)vs › | $51.78M | -11304.83% | -9549.74% | -8821.76% | -6347.57% |
| INmune Bio, Inc. (INMB)vs › | $51.84M | -91866.00% | -196225.86% | -104777.73% | -90977.38% |
| Lite Strategy, Inc. (LITS)vs › | $47.64M | 0.00% | 0.00% | -9.50% | -48.42% |
| Eloxx Pharmaceuticals, Inc. (ELOX)vs › | $53.11M | N/A | -24.71% | -12.36% | -8.24% |
| BioStem Technologies, Inc. (BSEM)vs › | $45.77M | -13.86% | -1.65% | -39.69% | -47.80% |
Operating Margin
-11541.5%
Net Profit Margin
-20059.9%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -14915.56% |
| 2026-03-31 | -53939.99% |
| 2025-12-31 | -11981.82% |
| 2025-09-30 | -58513.33% |
| 2025-06-30 | -27477.78% |
| 2025-03-31 | -927.16% |
| 2024-12-31 | -14889.01% |
| 2024-09-30 | -9179.31% |
| 2024-06-30 | -7456.04% |
| 2024-03-31 | -15178.08% |
| 2023-12-31 | -5984.12% |
| 2023-09-30 | -2238.89% |
| 2023-06-30 | -9346.84% |
| 2023-03-31 | -11000.00% |
| 2022-12-31 | -450.43% |
| 2022-09-30 | -6308.05% |
| 2022-06-30 | -12954.29% |
| 2022-03-31 | -44513.33% |
| 2021-12-31 | 2222.61% |
| 2021-09-30 | 26312.73% |
| 2021-06-30 | -1667.16% |
| 2021-03-31 | -18664.79% |
| 2020-12-31 | 2682.76% |
| 2020-09-30 | -10505.10% |
| 2020-06-30 | -64655.56% |
| 2020-03-31 | -5630.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
